// App-Quantinova.ai

ABS064 : CLEARANCE OF FIDANACOGENE ELAPARVOVEC VECTOR DNA IN PATIENTS WITH SEVERE OR MODERATELY SEVERE HEMOPHILIA B

Researchers

Presenter

  • A. Chhabra

Principal Investigators

  • P. F. Fogarty

  • I. Winburn

  • D. Rybin

  • W. Byon

  • J. D. Smith

  • J.-C. Marshall

  • J. W. Rupon

Medical Centers

  • Pfizer Inc, New York, NY

  • Pfizer Inc., Collegeville, United States

  • Pfizer Oncology, Surrey, United Kingdom

  • Pfizer Inc., Groton, United States

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Hemophilia

Biomarkers

  • Peripheral blood mononuclear cell

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved